Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | MAPT | P10636 | 6/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4730437 | 0.84 | HCAR3 (0.41) | RAF1HPGDALDH1A1MAPTHSD17B10 | |
| SCHEMBL11886208 | 0.82 | RAF1 (0.43) | RAF1HPGDALDH1A1MAPTHSD17B10 | |
| SCHEMBL669321 | 0.81 | RAF1 (0.39) | RAF1HPGDALDH1A1MAPTHSD17B10 | |
| SCHEMBL10265083 | 0.79 | ALDH1A1 (0.58) | RAF1HPGDALDH1A1MAPTKDM4E | |
| SCHEMBL2434313 | 0.78 | RAF1 (0.38) | RAF1HPGDALDH1A1MAPTHSD17B10 | |
| SCHEMBL14726870 | 0.78 | RAF1 (0.56) | RAF1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL318526 | 0.76 | KDM4E (0.53) | HPGDALDH1A1MAPTHSD17B10KMT2A | |
| SCHEMBL2157471 | 0.75 | MAPT (0.69) | HPGDALDH1A1MAPTKMT2AKDM4E | |
| SCHEMBL13545971 | 0.74 | MAPT (0.44) | HPGDALDH1A1MAPTHSD17B10KMT2A | |
| SCHEMBL24131808 | 0.74 | HPGD (0.42) | RAF1HPGDALDH1A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090136448-A1 | Antiviral 2-Carboxy-Thiophene Compounds | CORFIELD JOHN ANDREW | 2009-05-28 | — | — | US | disclosed |
| US-20090136448-A1 | Antiviral 2-Carboxy-Thiophene Compounds | CORFIELD JOHN ANDREW | 2009-05-28 | — | — | US | disclosed |
| EP-1971599-A1 | ANTIVIRAL 2-CARBOXY-THIOPHENE COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-09-24 | — | — | EP | disclosed |
| WO-2008043791-A2 | THIOPHENE DERIVATIVES FOR TREATING HEPATITIS C | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008043791-A2 | THIOPHENE DERIVATIVES FOR TREATING HEPATITIS C | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-17 | — | — | WO | disclosed |
| WO-2007071434-A1 | ANTIVIRAL 2-CARBOXY-THIOPHENE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090136448-A1 | Antiviral 2-Carboxy-Thiophene Compounds | EIF2AK2, HAVCR2, MAVS | RAF1 4415/4885HPGD 4655/4885ALDH1A1 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.